Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
Core Innovation
The invention provides TIM3-specific antibodies that specifically bind the extracellular domain of human TIM3, and binding results in internalization into a TIM3-expressing cell. The antibodies are defined by particular light chain and heavy chain complementarity determining region (CDR) sequence identifiers selected from a listed group.
The invention further characterizes rapid internalization into TIM3-expressing cancer cells, including cancer stem cells. The internalizing TIM3 antibodies are associated with inhibition of proliferation under cross-linked or multimerized conditions, and the document also supports complement dependent cytotoxicity (CDC) activity as a functional property.
The invention also encompasses therapeutic applications in which TIM3 internalizing antibodies are used to target cancer cells and to deliver cytotoxic agents, including in antibody-drug conjugate formats. The documented content includes cytokine modulation use via inhibition of Th1 cytokine release, including IL-6 and IFN-γ, from activated CD4+ T cells.
Claims Coverage
The provided claim set contains one independent claim directed to TIM3 extracellular domain-binding internalizing antibodies defined by specific light- and heavy-chain CDR sequence identifiers. The dependent claims refine antibody identity, format, and use-context while retaining the core internalizing TIM3-binding function.
Tim3 extracellular domain binding resulting in internalization
An antibody that specifically binds the extracellular domain of human T-cell Immunoglobulin Mucin (TIM) 3, wherein binding results in internalization into a TIM3-expressing cell.
Cdr sequence-defined tim3 internalizing antibody
The antibody is selected from the group consisting of antibodies having light chain CDR sequences of specified SEQ ID NOs and heavy chain CDR sequences of specified SEQ ID NOs as recited in options (i)-(v).
The independent claim requires a TIM3 extracellular-domain-specific antibody that causes internalization into TIM3-expressing cells, with the antibody identity constrained by specific combinations of light-chain and heavy-chain CDR SEQ ID NOs. The dependent claims further narrow the antibody format, constrain target cell context, and add composition context, without changing the core internalizing TIM3-binding requirement.
Stated Advantages
Rapid internalization into TIM3-expressing cancer cells, including cancer stem cells.
Inhibition of proliferation under cross-linked or multimerized conditions.
Complement dependent cytotoxicity (CDC) activity.
Ability to deliver cytotoxic agents via antibody-drug conjugates.
Inhibition of Th1 cytokine release, including IL-6 and IFN-γ, from activated CD4+ T cells.
Documented Applications
Diagnostic assays and detection/localization using labeled antibodies and methods such as flow cytometry/FACS, including in vitro or in vivo detection and theranostic use.
Therapeutic treatment of hematopoietic malignancies including leukemia (e.g., AML) and B cell lymphoma types described in the document.
Therapeutic treatment of solid tumors, with multiple tumor types listed in the document (e.g., colon, ovarian, liver, prostate, uterine, breast, and renal).
Anti-inflammatory use via inhibition of Th1 cytokine release (including IL-6 and IFN-γ) from activated CD4+ T cells.
Interested in licensing this patent?